Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ZAI LAB LIMITED

(ZLAB)
  Report
Real-time Estimate Cboe BZX  -  12:23 2022-11-29 pm EST
34.71 USD   +11.79%
10:55aHopes of Easing COVID Restrictions Boost Asian Equities
MT
11/18JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rating
MT
11/17Asian Equities Diverge From US Markets, Climb in Thursday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ZAI LAB LTD : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

09/27/2022 | 08:11am EST

Item 1.01 Entry into a Material Definitive Agreement.

On September 23, 2022, Zai Lab (Hong Kong) Limited, a wholly-owned subsidiary of Zai Lab Limited (the "Company"), and Seagen Inc. ("Seagen") entered into a collaboration and license agreement (the "Agreement"), pursuant to which the Company and Seagen agreed to collaboratively develop and commercialize TIVDAK® (tisotumab vedotin). Under the Agreement, the Company obtained from Seagen an exclusive license to develop and commercialize TIVDAK in mainland China, Hong Kong, Macau, and Taiwan (collectively, the "Licensed Territory").

Pursuant to the terms of the Agreement, the Company will pay Seagen an upfront payment of $30.0 million, as well as development and regulatory milestone payments up to an aggregate of $78.0 million upon the achievement of specified development and regulatory milestones and sales milestone payments of up to an aggregate of $185.0 million upon the achievement of specified sales milestones. Seagen will also be eligible to receive certain royalties at tiered percentage rates ranging from mid-teens to low twenties on annual net sales of licensed products in the Licensed Territory, subject to reduction under specified circumstances.

The Agreement will remain in effect, unless earlier terminated, until the expiration of the last-to-expire royalty term for the last licensed product. The Agreement contains customary provisions for termination by either party, including in the event of a material breach by the other party that remains uncured, by the Company for convenience, for certain bankruptcy events, and by Seagen upon a challenge of the licensed patent rights.

The foregoing description of the terms of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, which the Company intends to file as an exhibit to a subsequent periodic report or on an amendment to this Current Report on Form 8-K.

Item 7.01 Regulation FD Disclosure.

A copy of the press release announcing the Agreement is furnished as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.                                             Description

99.1                     Press Release issued by Zai Lab Limited on September 27, 2022

104                    The cover page of this Current Report on Form 8-K is formatted in Inline XBRL


--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about ZAI LAB LIMITED
10:55aHopes of Easing COVID Restrictions Boost Asian Equities
MT
11/18JPMorgan Chase Lowers Price Target on Zai Lab to $79 From $96, Maintains Overweight Rat..
MT
11/17Asian Equities Diverge From US Markets, Climb in Thursday Trading
MT
11/15Zai Lab Grants American Depositary Shares
MT
11/11Asian ADRs Surge Higher in Friday Trading as China Eases COVID-19 Restrictions
MT
11/11Citigroup Adjusts Price Target on Zai Lab to $127 From $199, Maintains Buy Rating
MT
11/10Asian ADRs Soar in Thursday Trading Following US Inflation Data
MT
11/10Transcript : Zai Lab Limited, Q3 2022 Earnings Call, Nov 10, 2022
CI
11/09Zai Lab's Q3 Net Loss Widens
MT
11/09Zai Lab Reports Wider Q3 Loss, Higher Revenue
MT
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations